Cargando…
Comment on “Levothyrox(®) New and Old Formulations: Are They Switchable for Millions of Patients?”
Autores principales: | Munafo, Alain, Krebs-Brown, Axel, Gaikwad, Sumedh, Urgatz, Bogumila, Castello-Bridoux, Claire |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584227/ https://www.ncbi.nlm.nih.gov/pubmed/31187469 http://dx.doi.org/10.1007/s40262-019-00785-x |
Ejemplares similares
-
Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
por: Krebs-Brown, Axel, et al.
Publicado: (2019) -
Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?
por: Concordet, Didier, et al.
Publicado: (2019) -
Authors’ Reply to Nicolas: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019) -
Authors’ Reply to Castello-Bridoux et al.: “Comment on Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019) -
Authors’ Reply to Coste et al.: “Levothyrox(®) New and Old Formulations: Are they Switchable for Millions of Patients?”
por: Concordet, Didier, et al.
Publicado: (2019)